Accelerating Recovery After ICU Admission: Post-discharge Supplementation With Pasteurized Akkermansia Muciniphila.

The goal of this clinical trial is to learn if daily oral supplementation with pasteurized Akkermansia muciniphila (PAM), an EFSA-approved food supplement, can support recovery in adults who have recently been treated in the ICU for sepsis. The main questions it aims to answer are: * Is PAM safe to take for 56 days after ICU discharge? * Does PAM increase the abundance of beneficial butyrate-producing bacteria in the gut? Researchers will compare PAM to a placebo (a capsule that looks the same but has no active ingredient) to see if PAM improves gut microbiota and immune recovery. Participants will: * Take PAM or placebo capsules once daily for 56 days * Provide stool and blood samples at baseline, day 28, and day 56 * Receive a follow-up phone call about their health 1 year after starting the study

NCT Number	NCT07295353
Lead Sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Collaborators: THE AKKERMANSIA COMPANY, ZonMw: The Netherlands Organisation for Health Research and Development
Conditions	Sepsis, Post Intensive Care Unit Syndrome, Critical Illness, Microbiome Dysbiosis, Intensive Care Unit Survivors
Enrollment	50 participants
Start Date	2026-01
Primary Completion	2028-01 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-19